ArticleWorld journal of gastrointestinal surgery2026
Admission hyperphosphatemia as a predictor of severity and mortality in acute pancreatitis: A 1000-patient cohort study.
Article in World journal of gastrointestinal surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough most acute pancreatitis (AP) cases are mild, up to 20% progress to severe disease, leading to substantial morbidity and mortality. Early risk stratification remains challenging because conventional scoring systems require multiple parameters and often depend on 24-48 hours of observation.
aimTo evaluate whether serum phosphate levels measured upon hospital admission can predict disease severity and short-term clinical outcomes in patients with AP.
methodsWe retrospectively analyzed 1000 consecutive patients hospitalized for AP between November 2023 and June 2025. Admission phosphate was categorized as hypophosphatemia (< 2.5 mg/dL), normophosphatemia (2.5-4.5 mg/dL), or hyperphosphatemia (> 4.5 mg/dL). Clinical outcomes included severe AP (SAP), pancreatic necrosis, intensive care unit (ICU) admission, and 30-day all-cause mortality. Multivariable logistic regression was performed to evaluate the independent association between phosphate levels and clinical outcomes, with additional models adjusted for creatinine levels and acute kidney injury (AKI).
resultsSAP occurred in 60% of patients with hyperphosphatemia and in 20% of those with normophosphatemia (
conclusionAdmission hyperphosphatemia independently predicts severe disease, pancreatic necrosis, ICU admission, and early mortality, highlighting a simple and inexpensive biomarker to support rapid risk stratification in AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.